Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Folic Acid for Acute Kidney Injury Feasibility Study
NCT07013136Phase 1Not yet recruiting
- Sponsor
- The University of Hong Kong
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of folic acid in acute kidney injury (AKI) (2 arms), sponsored by The University of Hong Kong. Primary endpoints: Feasibility of intervention at 30 days and 30-day Severe Adverse Events. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
folic acid
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07013136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013136.